Bloomberg Law
Bankruptcy
LinkedIn

Mallinckrodt Gets FDA Approval of sNDA for Acthar Gel Injector

March 1, 2024, 1:57 PM UTC
Allegra Fradkin
Allegra Fradkin

Mallinckrodt said the FDA has approved its supplemental New Drug Application for the Acthar Gel Single-Dose Pre-filled SelfJect Injector

  • Acthar delivery device for chronic and acute inflammatory and autoimmune conditions
  • Expected to launch in US in 2h 2024

To view the source of this information, click here

To contact the reporter on this story:
Allegra Fradkin in New York at afradkin@bloomberg.net

To contact the editor responsible for this story:
Sunil Kesur at skesur@bloomberg.net

© 2025 Bloomberg L.P. All rights reserved. Used with permission.

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.